-
公开(公告)号：US20220340648A1
公开(公告)日：2022-10-27
申请号：US17682082
申请日：2022-02-28
Applicant: UCB Biopharma SRL
Inventor： Patrick DOWNEY , Kerry Louise TYSON , Marco KRIEK , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN , Peter Charles ELLIOT , Terence Seward BAKER
Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20210132079A1
公开(公告)日：2021-05-06
申请号：US17143719
申请日：2021-01-07
Applicant: UCB Biopharma SRL
Inventor： James Philip O'CONNELL , John Robert PORTER , Alastair LAWSON , Daniel John LIGHTWOOD , Rebecca Jayne MUNRO
IPC: G01N33/68 , C07D401/14 , C07K14/525 , C07D471/00 , C07K14/705 , C07K16/24 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P37/00 , A61P35/00
Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
-
公开(公告)号：US20230176071A1
公开(公告)日：2023-06-08
申请号：US17923904
申请日：2021-05-06
Applicant: UCB BIOPHARMA SRL
Inventor： Anastasios SPILIOTOPOULOS , David James MCMILLAN , Michael John Wright , Sebastian KELM , Xiaofeng LIU , Daniel John LIGHTWOOD
IPC: G01N33/68
CPC classification number: G01N33/6857
Abstract: A method of identifying of amino-acid residues on a target protein that form a binding site of a molecule of interest. Such method relies on selection of relevant patches of solvent-accessible residues and testing of an array of mutated proteins for changes of binding properties. Such method is useful for determining binding sites (epitopes) of antibodies, ligands and related molecules.
-
公开(公告)号：US20210262024A1
公开(公告)日：2021-08-26
申请号：US17255316
申请日：2019-07-03
Applicant: UCB BIOPHARMA SRL
Inventor： Daniel John LIGHTWOOD , Michael John WRIGHT
IPC: C12Q1/6869 , C12Q1/6806
Abstract: The present disclosure relates to a duplex probe molecule comprising: i) a double-stranded-core (the core) comprising a first polynucleotide strand (first-strand) and a second polynucleotide strand (second-strand), wherein the first and second strands are complementary to each other, ii) a single stranded first polynucleotide probe (first probe) sequence extending in the 5′ to 3′ direction from the first-strand of the core; and iii) single stranded second polynucleotide probe (second probe) sequence extending in the 5′ to 3′ direction from the second strand of the core; wherein the first and second probes extend outwards from the double stranded core in opposing directions on different polynucleotide strands and each terminate in a 3′ end. The disclosure also extends to methods of making the molecule and use of the molecule, for example to capture variable domains sequence information from antibodies.
-
公开(公告)号：US20240067758A1
公开(公告)日：2024-02-29
申请号：US18255213
申请日：2021-12-06
Applicant: UCB BIOPHARMA SRL
Inventor： Joseph Michael David RASTRICK , John Paul SILVA , Daniel John LIGHTWOOD , Ralph ADAMS , Roger Thomas PALFRAMAN , Kerry Louise TYSON , Peter Charles ELLIOTT , Seema MAYANK , Andrea Julie CROSBY , Emily Mary Cairistine BARRY , Seppe Frans Roman LEYSEN , Zainab AHDASH
CPC classification number: C07K16/468 , C12N15/63 , A61P17/00 , C07K2317/31 , C07K2317/76 , C07K2317/565 , C07K2317/55 , C07K2317/622 , C07K2317/14
Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.
-
Patent Agency Ranking
公开(公告)号：US20220220192A1
公开(公告)日：2022-07-14
申请号：US17585174
申请日：2022-01-26
Applicant: UCB BIOPHARMA SRL
Inventor： Ralph ADAMS , Patrick DOWNEY , Terence Seward BAKER , Kerry Louise TYSON , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN
IPC: C07K16/18
Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20220025033A1
公开(公告)日：2022-01-27
申请号：US17500616
申请日：2021-10-13
Applicant: UCB BIOPHARMA SRL , SANOFI
Inventor： Alastair David Griffiths LAWSON , Daniel John LIGHTWOOD , Rebecca Jayne MUNRO , James Philip O'CONNELL , John Robert PORTER
IPC: C07K16/24
Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
-
公开(公告)号：US20210101964A1
公开(公告)日：2021-04-08
申请号：US16772043
申请日：2018-12-13
Applicant: UCB Biopharma SRL
Inventor： Patrick DOWNEY , Kerry Louise TYSON , Marco KRIEK , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN , Peter Charles ELLIOTT , Terence Seward BAKER
Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20210088530A1
公开(公告)日：2021-03-25
申请号：US17013326
申请日：2020-09-04
Applicant: UCB BIOPHARMA SRL
Inventor： James Philip O'CONNELL , John Robert PORTER , Alastair LAWSON , Boris KROEPLIEN , Stephen Edward RAPECKI , Timothy John NORMAN , Graham John WARRELLOW , Tracy Lynn ARAKAKI , Alex Buntin BURGIN , William Ross PITT , Mark Daniel CALMIANO , David Andreas SCHUBERT , Daniel John LIGHTWOOD , Rebecca Jayne MUNRO
IPC: G01N33/68 , C07D401/14 , C07K14/525 , C07D471/00 , C07K14/705 , C07K16/24 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P37/00 , A61P35/00
Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
-
公开(公告)号：US20240254224A1
公开(公告)日：2024-08-01
申请号：US18558686
申请日：2022-05-02
Applicant: UCB BIOPHARMA SRL
Inventor： Daniel John LIGHTWOOD , Irena KADIU , Pallavi BHATTA , Anastasios SPILIOTOPOULOS , Peter Charles ELLIOTT , James Martin KEANEY , Silvia L. DELKER , Jan ABENDROTH
CPC classification number: C07K16/2803 , A61P25/28 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antibodies binding to TREM1 and inhibiting its interaction with one or more of its natural ligands. Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such are also provided.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.017 seconds)
